



Pfizer supports deployment of 400 oxygen beds for adult and pediatric patients in Delhi and ICU beds in Mumbai COVID care facilities

Additional supply of essential COVID medicines valued at over Rs. 510-crore mobilized for Government hospitals

MUMBAI, INDIA, June 4, 2021: Pfizer announced today that it has partnered with the NGO Doctors For You to help create Oxygen Bed capacity at Delhi's Yamuna COVID Care Centre. With a grant of INR 4.50 crore (approx. US\$600,000), from Pfizer, Doctors For You has procured and deployed 400 high-quality beds with oxygen support and other medically-necessary equipment including high quality ventilators, oxygen cylinders, oxygen concentrators, laboratory equipment, consumables and services of medical and paramedical staff services to maintain the operations at the facility. 10% of these beds have been set up to specifically meet the requirements of COVID-19 pediatric patients.

The Yamuna COVID care facility primarily caters to mild and moderate cases, more broadly meeting the needs of lower income patients, migrant laborers, pediatric patients and others. Any severe cases that need ICU support get referred to Government tertiary care hospitals with ICU facilities. Partly funded by the Delhi Government, the facility is being run jointly by the Delhi Government and NGO Doctors For You.

In addition to the aid provided by Pfizer India, the Pfizer Foundation, based in the US donated US\$500,000 (INR 4 crore) grant to AmeriCares to support a 30-Bed ICU facility at the Bandra Kurla Complex Jumbo COVID Centre in Mumbai. With this support, the Foundation is helping mobilize critical equipment needed to make the ICU facility operational. These include more than 350 units of 40 different types of high-quality equipment such as ventilators, CNS monitors, patient monitors, syringe pumps and much more. The Foundation also provided a US\$500,000 grant to Direct Relief to fund the support, acquisition and distributions of critical medicines, medical supplies (including oxygen) and PPE. The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions.

Earlier this month, Pfizer Inc had announced its biggest ever humanitarian relief effort—with the donation of essential COVID medicines valued at over INR 510 crore (US\$70 million). The first consignment of 2.2 million units of essential medicines valued at approx. INR 50 crore has reached New Delhi and is being handed over to the Indian Red Cross Society by our NGO partner. The donation includes steroid medications to reduce inflammation, anticoagulants to help prevent blood clotting and antibiotics that treat secondary bacterial infections. These medicines have been identified as part of the Government of India's COVID treatment protocol and will soon start arriving in India for use in Government hospitals across the country.

"Pfizer is firmly committed to support India in its fight against the pandemic. We stand in solidarity with all those currently affected by COVID-19 in India and around the world and will continue to do everything possible to provide assistance in India's fight against COVID-19. These have been unprecedented times and ever since the beginning of the pandemic, our COVID-19 relief efforts have been focused towards supporting public health workers, governments authorities and our partners so that patients have access to the treatment they need," said, S. Sridhar, Managing Director, Pfizer Limited.

"During this turbulent and uncertain time, we are humbled by the support that Pfizer has extended to Doctors For You for converting the Yamuna Sports Complex in Delhi into a makeshift hospital that comprises 800 oxygen supported beds. During the crisis of second wave, the steadfast support from Pfizer is helping us save more lives and provide patients with utmost care and treatment to defeat the virus. With the aim of saving as many lives as possible during this pandemic, we could achieve this with Pfizer's generous contribution towards the cause," said, Dr. Rajat Jain, President, Doctors For You.



During the first wave of the pandemic in 2020, Pfizer had funded the procurement and deployment of critical and life-saving equipment including ventilators, oxygen concentrators, multipara monitors, crash carts, ECG machines, blood gas analyzer machines, nebulizers, and ABG machines, and personal protective material to over 400,000 healthcare workers across the country.

About Pfizer: Breakthroughs That Change Patients' Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizerindia.com.

Disclaimer

The information contained in this press release is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care of in the press release and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this press release or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries were such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this press release, independent consultation / advise may be obtained and necessary due diligence, investigation etc. may be done at your end.

Media Contact

Chikita Sobti

+ 91 98201 91347

Chikita.sobti@pfizer.com